Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cortical gray-white matter contrast alterations precede amyloid-β positivity and macrostructural changes in older adults without dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same author

A Practical Guide to PSMA PET Radiopharmaceuticals for Prostate Cancer Imaging, From the AJR Special Series on Molecular Imaging.

AJR. American journal of roentgenology·2026

Same author

Development and Implementation of a Radiation Safety Screening Protocol for a Clinical Study Using Amyloid Positron Emission Tomography Imaging.

Ochsner journal·2026

Same author

Integration of PSMA PET into the New Recommendations from Prostate Cancer Working Group 4 for Prostate Cancer Trials.

Journal of nuclear medicine technology·2026

Same author

Utility of Preclinical Dosimetry for First-in-Human Studies with PET Drugs Labeled with Common Radionuclides: A Systematic Review of Radiation Dose Estimates.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same author

Comparability of Centiloid values from [<sup>18</sup>F]flutemetamol scans using seven commercial and research software.

Neuroimage. Reports·2026

Same journal

Erratum.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same journal

Live from 2026 SNMMI Annual Meeting in Los Angeles!

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same journal

CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same journal

SSTR-Targeted Radiotheranostics in Breast Cancer: A Comparison of [<sup>68</sup>Ga]Ga-DOTATOC and [<sup>68</sup>Ga]Ga-SSO120 with [<sup>18</sup>F]FDG PET.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same journal

Prognostic Value of Restaging [<sup>18</sup>F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same journal

Radiation-Induced Senescence in Radiopharmaceutical Therapy: Mechanisms and Therapeutic Implications.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 30, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

Quantitative Brain Amyloid PET.

William J Jagust¹, Venkata S Mattay², Daniel M Krainak³

¹University of California, Berkeley, California.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine

|March 21, 2024

Summary

This summary is machine-generated.

Quantitative amyloid PET imaging shows promise for Alzheimer's disease assessment, but challenges remain for clinical use. Experts convened to discuss its role in staging, prognosis, and monitoring disease progression.

Keywords:

PET amyloid centiloid dementia quantification

More Related Videos

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

A Dual Tracer PET-MRI Protocol for the Quantitative Measure of Regional Brain Energy Substrates Uptake in the Rat

A Dual Tracer PET-MRI Protocol for the Quantitative Measure of Regional Brain Energy Substrates Uptake in the Rat

Published on: December 28, 2013

Related Experiment Videos

Last Updated: Jun 30, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

A Dual Tracer PET-MRI Protocol for the Quantitative Measure of Regional Brain Energy Substrates Uptake in the Rat

A Dual Tracer PET-MRI Protocol for the Quantitative Measure of Regional Brain Energy Substrates Uptake in the Rat

Published on: December 28, 2013

Area of Science:

Neurology
Radiology
Nuclear Medicine

Background:

Amyloid PET imaging tracers have increased interest in quantifying brain amyloid burden in Alzheimer's disease (AD).
Quantitative amyloid PET imaging offers potential for disease staging, theranostics, monitoring, and outcome measurement in clinical trials.
Significant challenges hinder the widespread clinical implementation of quantitative amyloid PET imaging.

Purpose of the Study:

To summarize discussions from a public workshop on the role of quantitative brain amyloid PET imaging in Alzheimer's disease.
To explore the utility of quantitative amyloid PET imaging for staging, prognosis, and longitudinal assessment of AD.
To identify key challenges and future directions for quantitative amyloid PET imaging in clinical practice.

Main Methods:

A public workshop was cosponsored by the U.S. FDA, SNMMI, and MITA on November 17, 2022.
Experts from academia, industry, and government agencies participated in the workshop.
Presentations and discussions covered various aspects of quantitative amyloid PET imaging.

Main Results:

The workshop addressed available radiopharmaceuticals for amyloid imaging.
Methodology, metrics, and analytic validity of quantitative amyloid PET imaging were discussed.
The application of quantitative amyloid PET imaging in disease staging, prognosis, and progression monitoring was explored, alongside existing challenges.

Conclusions:

Quantitative amyloid PET imaging holds significant potential for Alzheimer's disease management and research.
Addressing current challenges is crucial for the successful integration of quantitative amyloid PET imaging into routine clinical practice.
Continued collaboration and research are needed to optimize the use of quantitative amyloid PET imaging for Alzheimer's disease.